Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis

Juhwan Lee; Rine Nakanishi; Dong Li; Kashif Shaikh; Chandana Shekar; Kazuhiro Osawa; Negin Nezarat; Eranthi Jayawardena; Maja Blanco; Matthew Chen; Matthew Sieckert; Eric Nelson; Darius Billingsley; Sajad Hamal; Matthew J Budoff

doi:10.1016/j.ahj.2018.08.007

Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis

Am Heart J. 2018 Dec:206:127-130. doi: 10.1016/j.ahj.2018.08.007. Epub 2018 Aug 24.

Authors

Affiliations

¹ Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA.
² Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA. Electronic address: [email protected].

PMID: 30227941
DOI: 10.1016/j.ahj.2018.08.007

Abstract

Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Anticoagulants / administration & dosage
Atherosclerosis / diagnosis
Atherosclerosis / drug therapy*
Coronary Angiography
Coronary Artery Disease / diagnosis
Coronary Artery Disease / drug therapy*
Dose-Response Relationship, Drug
Factor Xa Inhibitors / administration & dosage
Female
Humans
Male
Middle Aged
Randomized Controlled Trials as Topic / methods*
Rivaroxaban / administration & dosage*
Warfarin / administration & dosage*

Substances

Anticoagulants
Factor Xa Inhibitors
Warfarin
Rivaroxaban